Multibagger Selection: DeepSeek's picks
DeepSeek picked INOD, RZLV, FEIM, PVLA, AGIO with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | DeepSeek |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | INOD | — | 78% | — | — |
| 2 | RZLV | — | 62% | — | — |
| 3 | FEIM | — | 68% | — | — |
| 4 | PVLA | — | 55% | — | — |
| 5 | AGIO | — | 60% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | -1.79% | -1.75% | 1.14x | 0 |
The model's market view
The small- and mid-cap universe in late October 2026 offers a narrow but real set of multibagger setups: AI infrastructure suppliers with visible revenue acceleration and operating leverage, hyper-growth software platforms still valued at low single-digit revenue multiples, and binary FDA catalysts where approval would re-rate the equity. Liquidity remains adequate in the $200 million to $5 billion market-cap band, but balance-sheet quality and dilution risk separate the credible candidates from the speculative ones. The strongest evidence-backed setups combine an identifiable 12-month catalyst with either positive free cash flow already inflecting or a funded path to commercial launch.
Why each pick
INOD
Innodata is an AI data-engineering provider whose revenue is accelerating, gross margins are expanding, and free cash flow has inflected sharply positive. Q2 2026 revenue rose 58% year over year to $92.1 million, gross margin reached 49% versus 40% a year earlier, and operating cash flow for the first half of 2026 was $164.4 million versus $15.0 million in the year-ago period. The customer base is diversifying, with the largest customer falling to 37% of Q2 revenue from 56% in Q1. The stock trades at a premium but the growth and margin trajectory leave room for further appreciation if AI data demand persists. The near-term catalyst is Q3 2026 earnings on November 5, 2026, with management reiterating full-year 2026 revenue growth of at least 40%.
RZLV
Rezolve AI is a hyper-growth commerce AI platform whose revenue exploded to $130.8 million in H1 2026 from $6.3 million a year earlier, and management has guided full-year 2026 revenue to approximately $360 million. At a $654 million market cap, the stock trades at roughly 1.8x guided 2026 revenue, an extremely low multiple for a company growing at triple-digit rates. Gross margin was 48.9% in H1 2026, and management has outlined a credible path to positive EBITDA by mid-2027 through $60 million of cost cuts and lower cash burn in the second half of 2026. The analyst consensus is Strong Buy with a price target of $10, far above the current $1.57 price, indicating substantial perceived upside if execution continues.
FEIM
Frequency Electronics is a precision timing and frequency-control company serving space and defense programs that has inflected from a multi-year turnaround into a high-growth phase. Fiscal Q1 2027 revenue jumped 70% year over year to $23.45 million, gross margin reached 45.8%, and net income was $4.22 million. Most importantly, the company reported a record fully funded backlog of $129 million, up 82% year over year and 16% sequentially, providing unusually high visibility for the next 12 months. With a debt-free balance sheet, $61.4 million in cash, and a $724 million market cap, the valuation leaves substantial room for appreciation if the backlog converts into revenue and margins hold.
PVLA
Palvella Therapeutics is a late-stage rare-disease biotech with a near-term binary catalyst: its NDA for QTORIN rapamycin in microcystic lymphatic malformations is under FDA review, and management expects to announce the PDUFA date by the end of October 2026, with a potential approval and commercial launch in the first half of 2027. The market opportunity is estimated at $1–3 billion in peak sales across MLM and cutaneous venous malformations, and the company is funded with $250.6 million in cash. The stock has a Strong Buy consensus with an average price target of $231.25, well above the current $123.92, but the thesis is binary and dependent on FDA approval and launch execution.
AGIO
Agios Pharmaceuticals offers a near-term, verifiable FDA catalyst: the PDUFA date for mitapivat in sickle cell disease is November 1, 2026, following a Priority Review. Mitapivat revenue is already growing rapidly, reaching $44.7 million in Q2 2026 versus $12.5 million a year earlier, and a sickle cell approval would expand the label into a much larger market. The company has $964.8 million in cash and a low debt load, giving it ample runway. The stock trades at a premium to near-term revenue, but the SCD launch represents a material inflection that is not yet reflected in the current $2.19 billion market cap if the launch succeeds.
Other models on the same run
| Model | Picks |
|---|---|
| Muse Spark 1.1 | LUNR, ACHR, VERA, ENVX, SMR |
| Perplexity | PGY, AEHR, MAZE, AAPG, RGTI |
| Gemini 3 Pro | LUNR, RDW, SOUN, ACMR, RGTI |
| Claude Opus 5.5 | RCAT, LPTH, ONDS, AEHR, CAPR |
| Grok 4.5 | INOD, NRIX, PVLA, CALX, FEIM |
| GPT-6 | BKSY, AMPX, RCAT, RDW, EOSE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.